Non-Hodgkin's Lymphoma Treatment
Introduction to Non-Hodgkin's Lymphoma
- Non-Hodgkin's lymphoma (NHL) is a type of cancer that requires proper diagnosis and treatment, with guidelines provided by the National Comprehensive Cancer Network and other authorities 1, 2, 3
Diagnostic Approach
- The diagnostic approach for lymphoma should include surgical specimen/excisional lymph node biopsy with immunohistochemistry, complete blood count and chemistry, CT scan of chest and abdomen, bone marrow aspirate and biopsy, and consideration of PET scanning for better disease delineation 2, 3
The recommended diagnostic tests and their corresponding recommendations are:
Diagnostic Test Recommendation Surgical specimen/excisional lymph node biopsy Obtain with immunohistochemistry Complete blood count and chemistry Perform as part of diagnostic workup CT scan of chest and abdomen Perform as part of diagnostic workup Bone marrow aspirate and biopsy Perform as part of diagnostic workup PET scanning Consider for better disease delineation, regardless of white blood cell count - CT scan of chest, abdomen, and pelvis (with or without PET) is necessary for staging, as suggested by the Blood and Annals of Oncology guidelines 4, 5
- Bone marrow biopsy is required for aggressive subtypes and optional for indolent types, according to the Blood guidelines 4
- Cytogenetic studies (FISH) to detect prognostic markers like del(17p) or del(11q) should be performed to assess disease prognosis, according to the Journal of the National Comprehensive Cancer Network and the National Comprehensive Cancer Network 1, 6, 7
First-Line Treatment
- The standard first-line treatment regimen for CD20-positive DLBCL is R-CHOP, consisting of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, with dosing and cycles adjusted based on patient age and risk factors, as recommended by the National Comprehensive Cancer Network 1
- R-CHOP regimen consists of rituximab (375 mg/m² intravenously on day 1 of each cycle), cyclophosphamide (750 mg/m² intravenously on day 1), hydroxydaunorubicin/doxorubicin (50 mg/m² intravenously on day 1), oncovin/vincristine (1.4 mg/m² intravenously on day 1), and prednisone (100 mg orally on days 1-5) 1
- Six cycles of R-CHOP given every 14 days (R-CHOP-14) with eight doses of rituximab may be considered 8
- Alternatively, patients with early-stage disease (I-II) may receive three cycles of R-CHOP plus involved field radiation 8
- Young patients (≤60 years) with low-risk disease should receive 6-8 cycles of R-CHOP given every 21 days 2
- Young high-risk patients (aaIPI ≥2) should receive 6-8 cycles of R-CHOP given every 14-21 days; consider clinical trials 2
- Elderly patients (>60 years) should receive 8 cycles of R-CHOP given every 21 days or 6 cycles of R-CHOP-14 (given every 14 days) 2
- Patients 60-80 years old should receive 6-8 cycles of R-CHOP with eight doses of rituximab given every 21 days, according to the European Society for Medical Oncology 9
- For patients over 80 years old, R-miniCHOP (attenuated doses) is recommended by the European Society for Medical Oncology 9
- Bendamustine-rituximab is a treatment option for older patients or those with comorbidities 10
Post-Treatment Assessment and Follow-Up
- PET-CT is the recommended standard for post-treatment assessment to define complete remission, especially important for evaluating response in bulky sites 9
- PET-CT scan is highly recommended for post-treatment assessment to define complete remission 8
- Abnormal radiological tests at baseline should be repeated after 3-4 cycles and after the last cycle 8
- Bone marrow biopsy should be repeated at the end of treatment only if initially involved 8
- Follow-up should include history and physical examination every 3 months for 1 year, every 6 months for 2-3 more years, then annually, as well as blood count and LDH at 3, 6, 12, and 24 months, and CT scan at 6, 12, and 24 months after treatment 8
- History and physical examination should be performed every 3 months for 1 year, every 6 months for 2-3 more years, and then annually, as recommended by the Annals of Oncology guidelines 11
- Blood count and LDH should be monitored at 3, 6, 12, and 24 months, and radiological examinations should be performed at 6, 12, and 24 months after treatment completion, according to the Annals of Oncology guidelines 11
Relapsed/Refractory Disease
- For transplant-eligible patients (<65-70 years), salvage regimens (rituximab plus chemotherapy) followed by high-dose therapy with stem cell support may be considered 8
- Options for salvage regimens include R-DHAP, R-ESHAP, and R-ICE 8
- Patients <65 years with relapsed/refractory disease should receive salvage chemotherapy (R-DHAP, R-ICE, R-ESHAP) followed by high-dose therapy with stem cell support in responsive patients 12
- Patients ≥65 years or unfit for high-dose therapy should receive conventional salvage regimens (R-GEMOX) or clinical trials 12
- Rituximab monotherapy (375 mg/m² weekly for 4 weeks) is an option for relapsed/refractory disease 13
- Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin) is an option for relapsed/refractory disease 14
- Ibrutinib (Bruton tyrosine kinase inhibitor) is an option for relapsed/refractory disease 15
Special Considerations
- Special precautions are required in cases with high tumor load to prevent tumor lysis syndrome 8
- Dose reductions due to hematological toxicity should be avoided; consider growth factor support instead 8
- CNS prophylaxis should be considered in high-risk patients 8
- Cardiac monitoring is required when anthracyclines are used in patients with impaired cardiac function 1
- Thyroid function evaluation is recommended at 1, 2, and 5 years if neck was irradiated 13
- Women who received chest irradiation at premenopausal age should be screened for secondary breast cancers 13
- Central nervous system prophylaxis should be considered in high-risk patients, especially with involvement of bone marrow, testis, spine, or base of skull 2
Prognosis and Survival
- Younger patients (<60 years) have better outcomes with 5-year overall survival rates of approximately 60-70%, according to the American Society of Hematology 3
- Patients aged 60-80 years have 5-year overall survival rates of approximately 43.5%, as reported by the American Society of Hematology 16
- Patients >80 years have lower survival rates, but R-miniCHOP can still induce complete remission and meaningful survival, according to the American Society of Hematology 3, 16
- Localized disease (Stage I-II) has a better prognosis with 5-year survival rates of approximately 80-90%, as reported by the American Society of Hematology 3, 9
- Advanced disease (Stage III-IV) has lower survival rates, approximately 60-70% at 5 years, according to the American Society of Hematology 3, 9
- Early progression within 24 months of diagnosis in FL is associated with poor survival (5-year OS rate of 50% vs 90%), as per the National Comprehensive Cancer Network guidelines 17